© Copyright 2012, vLex. All Rights Reserved.
- Language
Contents in vLex United States
Explore vLex
For Professionals
For Partners
Company
WAYNE, N.J., Aug. 24, 2011 /PRNewswire/ -- Toys"R"Us, Inc. today announced it will host its fifth "Great Trade-In" event in Babies"R"Us(R) and Toys"R"Us(R) stores nationwide from Friday, August 26 through Sunday, September 18, once again providing parents and caregivers with the opportunity to trade-in used and potentially unsafe baby gear in exchange for 25% savings on a new item. Since the company launched its first "Great Trade-In" event in August 2009, nearly half a million items have been turned in at its stores across the country. In an effort to help parents and caregivers remove even more unsafe products from circulation, four new product categories -- swings, walkers, bouncers and entertainers -- have been added to the "Great Trade-In" event. The "Great Trade-In" event is a nat...
WAYNE, N.J., May 11, 2011 /PRNewswire/ -- Toys"R"Us, Inc. today announced plans to add the largest rooftop solar power installation in North America to its distribution center in Flanders, NJ. Staging for the system is currently underway and construction will conclude this summer. Upon completion, the 5.38 megawatt on-site solar mechanism will occupy 869,294 square feet and is estimated to generate 72 percent of the electrical needs for the Toys"R"Us(R) facility. The unprecedented scope of this project furthers our already strong commitment to sustainability in our operations," said Jerry Storch, Chairman and CEO, Toys"R"Us, Inc. "New Jersey's leadership in providing renewable, clean energy opportunities for companies has helped pave the way for an installation of this size and undersc...
HORSHAM, Pa., July 22, 2011 /PRNewswire/ -- Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response letter for its supplemental Biologics License Application (sBLA) for SIMPONI(R) (golimumab). The application, filed in September 2010, seeks to expand the SIMPONI(R) physician label to include inhibiting the progression of structural damage, inducing major clinical response (MCR) and maintenance of reduction of signs and symptoms and maintenance of improved physical function in the treatment of moderately to severely active rheumatoid arthritis (RA). Janssen Biotech, Inc. intends to request an end-of-review meeting with the FDA to thoroughly understand the details of the Complete Response letter and discuss future steps to achieve ...
ver las páginas en versión mobile | web
ver las páginas en versión mobile | web
© Copyright 2012, vLex. All Rights Reserved.
Contents in vLex United States
Explore vLex
For Professionals
For Partners
Company